Clarity Pharmaceuticals ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with ...

Esophageal cancer remains one of the world's deadliest cancers, ranking 7th in incidence and 6th in cancer-related deaths ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

In the realm of colorectal cancer treatments beyond surgery and radiation, one key question gained prominence in recent years ...

Chronic inflammatory bowel disease is challenging to treat and carries a risk of complications, including the development of bowel cancer. Young people are particularly affected: when genetic ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Medically reviewed by Jay N. Yepuri, MD Irritable bowel syndrome (IBS) and colon cancer are conditions that affect the colon, ...

Cancer remains one of the major global health threats. Tumors are not only influenced by gut microbiota but can also actively ...

A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to ...